SCHEMBL28549538

SCHEMBL28549538

CN1CCN(CCOc2nccc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)n2)CC1

nearest known ligand 0.50

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 15/20 0.50
▸ ERBB2 P04626 15/20 0.50
▸ ERBB3 P21860 12/20 0.50
▸ ERBB4 Q15303 12/20 0.50
▸ NTRK1 P04629 1/20 0.47
▸ CTSC P53634 2/20 0.47
▸ LTA4H P09960 1/20 0.44
▸ AIMP2 Q13155 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30213768 0.91 EGFR (0.51) EGFRERBB2ERBB3ERBB4CTSC
SCHEMBL30213672 0.88 EGFR (0.51) EGFRERBB2ERBB3ERBB4NTRK1
SCHEMBL28544852 0.86 EGFR (0.49) EGFRERBB2ERBB3ERBB4NTRK1
SCHEMBL28539471 0.85 EGFR (0.48) EGFRERBB2ERBB3ERBB4NTRK1
SCHEMBL30213684 0.79 EGFR (0.54) EGFRERBB2ERBB4NTRK1AIMP2
SCHEMBL28540768 0.79 EGFR (0.54) EGFRERBB2ERBB4NTRK1AIMP2
SCHEMBL28539872 0.79 ERBB2 (0.59) EGFRERBB2
SCHEMBL28537354 0.78 EGFR (0.63) EGFRERBB2ERBB3ERBB4
SCHEMBL30213815 0.78 EGFR (0.50) EGFRERBB2ERBB3ERBB4CTSC
SCHEMBL28552919 0.77 EGFR (0.43) EGFRERBB2ERBB3ERBB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112574177-A Pyrimidine derivatives and application thereof in preparing antitumor drugs 陕西师范大学 2021-03-30 — — CN claimed
CN-112574177-B Pyrimidine derivatives and application thereof in preparing antitumor drugs 陕西师范大学 2023-01-31 — — CN disclosed
CN-112574177-A Pyrimidine derivatives and application thereof in preparing antitumor drugs 陕西师范大学 2021-03-30 — — CN disclosed
Send feedback